Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature medicine, 2016 - nature.com
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of through the induction of angiogenesis, tumor …

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature Medicine, 2016 - go.gale.com
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of through the induction of angiogenesis, tumor …

[PDF][PDF] Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Nat Med, 2016 - academia.edu
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of inducing angiogenesis, some cancers …

[PDF][PDF] Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Nat Med, 2016 - core.ac.uk
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of inducing angiogenesis, some cancers …

[引用][C] Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature Medicine, 2016 - cir.nii.ac.jp
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature …, 2016 - diva-portal.org
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of through the induction of angiogenesis, tumor …

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.

S Frentzas, E Simoneau, VL Bridgeman… - Nature …, 2016 - europepmc.org
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of inducing angiogenesis, some cancers …

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature …, 2016 - research.monash.edu
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of through the induction of angiogenesis, tumor …

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature Medicine, 2016 - cris.bgu.ac.il
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of through the induction of angiogenesis, tumor …

[HTML][HTML] Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

S Frentzas, E Simoneau, VL Bridgeman… - Nature …, 2016 - ncbi.nlm.nih.gov
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that
are poorly understood. Notably, instead of inducing angiogenesis, some cancers …